Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

108.22
-0.5800-0.53%
Post-market: 108.610.3900+0.36%19:59 EDT
Volume:6.63M
Turnover:720.26M
Market Cap:134.62B
PE:22.88
High:110.90
Open:109.85
Low:108.04
Close:108.80
Loading ...

TD Cowen Keeps Their Buy Rating on Gilead Sciences (GILD)

TIPRANKS
·
06 May

Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating

MT Newswires Live
·
05 May

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Zacks
·
05 May

1 Profitable Stock on Our Watchlist and 2 to Turn Down

StockStory
·
05 May

Gilead Sciences (GILD) Gets a Buy from Mizuho Securities

TIPRANKS
·
03 May

Wolfe Research Adjusts Gilead Sciences Price Target to $115 From $110

MT Newswires Live
·
02 May

Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest

Simply Wall St.
·
01 May

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
30 Apr

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire
·
30 Apr

Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit

MT Newswires Live
·
30 Apr

U.S. Attorney in Manhattan Announces $202 Mln Settlement With Gilead Sciences for Using Speaker Programs to Pay Kickbacks to Doctors

THOMSON REUTERS
·
30 Apr

Gilead Sciences reaches $202 million settlement with US over kickbacks to doctors

Reuters
·
30 Apr

Gilead Sciences (NasdaqGS:GILD) Showcases Promising Liver Disease Treatments At EASL Congress

Simply Wall St.
·
30 Apr

Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States

ACCESS Newswire
·
29 Apr

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Business Wire
·
29 Apr

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Business Wire
·
29 Apr

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks

Dow Jones
·
28 Apr

Gilead Sciences First Quarter 2025 Earnings: Misses Expectations

Simply Wall St.
·
26 Apr

Gilead Sciences’ Earnings Call: Growth Amid Challenges

TIPRANKS
·
26 Apr

Gilead Sciences Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
26 Apr